Quel est le prix pour GenSight Biologics S.A. (SIGHT)

Le prix pour GenSight Biologics S.A. (SIGHT) est $0.12027613

Quelle est la capitalisation boursière pour GenSight Biologics S.A. (SIGHT)

La capitalisation boursière pour GenSight Biologics S.A. (SIGHT) est $19.61M

Bénéfices de GenSight Biologics S.A. (SIGHT)

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Année	Bénéfices	Changez
Pas assez de données pour les dates fournies.

Année

Bénéfices

Changez

Pas assez de données pour les dates fournies.

Entreprise	Bénéfices	Différence de bénéfices	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Entreprise

Bénéfices

Différence de bénéfices

Pays